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Abstract
A previous genetic analysis comparing the Dahl salt-sensitive (S) rat to the spontaneously
hypertensive rat (SHR) identified a major locus on chromosome 2 that influences proteinuria in
the S rat. In the present study, blood pressure, proteinuria, and renal hemodynamics were
evaluated in congenic strains with small segments of the protective SHR genome on the S
background. Proteinuria and renal function were significantly improved in the congenic strains
compared to the S. The causative locus interval was narrowed to <375 kb based on congenic
strains, haplotype data, comparative mapping, and concordance with human genetic studies.
Sequencing of the coding region of genes in this region identified 36 SNPs (13 nonsynonymous
and 23 synonymous). Gene expression profiling indicated that only few genes exhibited
differential expression. Arhgef11, Pear1, and Sh2d2 were identified as important candidate genes
that may be linked to kidney injury in the S rat. In particular, Arhgef11 plays an important role in
the activation of the Rho-ROCK signaling pathway. Inhibition of this pathway using fasudil
resulted in a significant reduction of proteinuria in treated S rats (compared to untreated S).
However, no difference was observed between treated or untreated SHR or congenic strains. The
homologous region in humans was found to be associated with estimated glomerular filtration rate
(eGFR) in the Candidate Gene Association Resource (CARe) population. In summary, these
findings demonstrate that allelic variants in Arhgef11, acting through the Rho-ROCK pathway,
could influence kidney injury in the S as well as provide insight into human kidney disease.
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Chronic kidney disease (CKD) affects ~10% of adults in the United States1. Those with
CKD initially demonstrate some sign of kidney injury (usually defined by proteinuria) and
as kidney injury worsens there can be a significant decline in kidney function that results in
increased risk for renal failure as well as cardiovascular disease. Extensive evidence
supports the premise of genetic susceptibility for kidney disease.2 The strong impact of
genetics on kidney disease is highlighted by the significant disparity in the prevalence
kidney disease in African Americans (~4 fold increase) with hypertension or diabetes
compared to Caucasians3. A number of large-scale genome wide association analysis
(GWAS) have identified single nucleotide polymorphism (SNP) associated with kidney
injury, but for the most part these studies only account for a very small change in renal
injury or a decline in renal function (as reviewed 4). Therefore, there is a critical need to
identify new genes and signaling pathways that might be involved in susceptibility and
progression of kidney injury.
The Dahl salt-sensitive (S) rat is a commonly used genetic model to study salt-sensitive
hypertension. Moreover, the S rat develops significant kidney injury, including
glomerulosclerosis, tubulointerstitial fibrosis, and vascular hypertrophy5. Kidney injury in
the S rat becomes more severe as blood pressure is increased when challenged with a high-
salt diet6, 7 similar to human patients that exhibit hypertensive nephrosclerosis 8. In contrast,
the spontaneously hypertensive rat (SHR) is resistant to hypertension associated kidney
injury. Using a segregating population derived from the S and SHR, we previously
demonstrated that there were 9 genomic regions associated with kidney injury in the S
rat7, 9. Some genomic intervals were associated with both increased blood pressure as well
as kidney injury, while other regions appeared to influence kidney injury independent of
blood pressure changes. In particular, the locus on rat chromosome 2 demonstrated strong
linkage (LOD >12) and accounted for a large amount of variation in proteinuria.
Recombinant progeny testing (RPT) narrowed the region of interest on chromosome 2 to
~6Mb. The homologous region on human chromosome 1 has been also associated with
various types of kidney disease10, 11. However, the sequence variants, genes, and/or
signaling pathways linked to this locus remain to be determined in the rat or humans.
The present study utilized RPT, congenic strains, haplotype analysis, sequencing, and gene
expression to establish a small number of genetic variants associated with increased
susceptibility of the S rat to develop kidney injury and associated decline in kidney function.
The first aim was to characterize the blood pressure and renal parameters associated with the
gene or genetic variants within the quantitative trait locus (QTL) for proteinuria on
chromosome 2. Thus, temporal changes in blood pressure, proteinuria, and renal
hemodynamics were evaluated by comparing S rats to two congenic strains carrying small
SHR chromosome 2 segments. The second aim sought to identify sequence variants and
gene expression differences in genes located in the newly identified small genomic segment.
Finally, to validate the importance of the genetic locus, the candidate region was evaluated
using a large-scale human population of CKD patients.
MATERIAL AND METHODS
The detailed methods are described in an expanded material and methods section in online
supplemental data.
Animals and Study Design
All experiments were approved by the Institutional Animal Care and Use Committee at
either the Medical College of Wisconsin (MCW) or the University of Mississippi Medical
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Center (UMMC). The Dahl salt-sensitive (S) and the spontaneously hypertensive rat (SHR)
inbred strains are maintained at our institutional animal facility.
Study 1: Fine-Mapping using Recombinant Progeny Testing (RPT) and
Congenic Strains—Recombinant Progeny Testing (RPT) was used to fine-map the
proteinuria locus as done previously12. Proteinuria was determined at week 8 in six
recombinant families (X39, n=67; X40, n=38; X41, n=37; X42, n=37; X43, n=21; X44,
n=23) (Table S1). The congenic strains, S.SHR(2) X39 and X47 were developed from the
recombinant families by fixing the transferred genomic interval in the homozygous SHR/
SHR state (Fig. 1). These congenic strains were utilized for Studies 2-6.
Study 2: Proteinuria, Blood Pressure and Renal Hemodynamic Parameters—
At 4 weeks of age, groups of age matched male S, S.SHR(2)X39, and SHR animals (n=6-8
per group) were weaned onto a low-salt diet (0.3% NaCl; TD7034; Harlan Teklad, Madison,
WI). At week 12, mean arterial pressure (MAP), renal blood flow (RBF) and glomerular
filtration rate (GFR) were measured.
Study 3: Time Course Measurement of Proteinuria and Telemetry Blood
Pressure—At 4 weeks of age, groups of age matched male S and S.SHR(2) X47 rats
(n=16 per group) were weaned to a low-salt diet (0.3% NaCl). Proteinuria and blood
pressure were measured from week 8 to 20 at 4 week intervals. Blood pressure was
measured using a telemetry system (Data Sciences International, St. Paul, MN) in S (n=8)
and S.SHR(2)X47 (n=10) animals as done previously13.
Study 4: Glomerular Permeability and Number—The reflection coefficient of
albumin (σalb) was determined in isolated glomeruli from S and S.SHR(2)X39 raised on a
low-salt diet (week 12) using modifications of the Savin technique14. These experiments
were performed using 4-5 rats per strain with a minimum of 20 glomeruli per rat (n=80-100
total glomeruli per group). The determination of glomeruli number was performed using
direct maceration/counting method15 using kidneys isolated at two time points (week 6 and
week 12).
Study 5: Renal Function and Survival Curve—At 4 weeks of age, groups of age
matched male S and S.SHR(2)X39 animals (n=9 per group) were weaned to a normal rodent
chow (0.7% NaCl; Purina 5010) to exacerbate hypertension and progression of injury
compared to a low-salt diet. Proteinuria and creatinine clearance (CrCl) was determined at
week 12. MAP, GFR, and RBF autoregulation was evaluated in a separate group of animals
(n=7-8 per group). A survival study was performed on S, S.SHR(2)X39, and SHR rats (n=12
rats per group).
Study 6: Pharmacological Inhibition of Rho-ROCK Pathway—Groups of age
matched male S, S.SHR(2)X39, and SHR animals (n=11 per group) were weaned onto low-
salt diet (0.3% NaCl) at week 4. At week 8, animals for each strain were randomly assigned
to either control (n=5 per strain) or fasudil treatment (n=6 per strain). Fasudil (LC
Laboratories, MA) was provided in drinking water to achieve a low dose of ~20 mg/kg/day.
Proteinuria was determined at week 8, 10, and 12 after 24-hour urine collection.
Histological Assessment
Kidney tissue was fixed in zinc formalin and embedded in paraffin, cut into 4-μm sections
and stained with hematoxylin and eosin (H&E) and/or Masson’s Trichrome. Glomerular
injury and tubulointerstitial injury were assessed as previously described5, 16, 17.
Immunohistochemistry was performed as previously described5.
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Genotyping and Sequencing—Genomic DNA was used to genotype congenic strains
or sequencing and prepared using Wizard SV 96 Genomic DNA kit. Genotyping was done
using a fluorescent-based approach on a Beckman Coulter CEQ8000 XL capillary sequencer
as described previously12. For sequencing of coding regions of candidate genes, primers
were designed from known databases (Table S2).
Real-Time PCR and Multiplex Gene Expression—RNA was extracted using Trizol®
reagent (Invitrogen, Carlsbad, CA) and purified using Mini RNeasy kit (Qiagen,Valencia,
CA ). cDNA was obtained by reverse transcription using the SuperScript III First-Strand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Gene expression was evaluated
using SYBR-green dye chemistry on a Stratagene MX3000p Real-Time PCR machine, Bio-
Rad CFX96, and Beckman Coulter GeXP platform (minimum n=6 each strain).
Western blot analysis—Tissue homogenates were prepared in RIPA lysis buffer (Santa
Cruz Biotechnology) from kidney cortex isolated from S and S.SHR(2)X39 under Study 2.
Blots were prepared using standard methods and probed with Rho-ROCK pathway proteins
(Arhgef11, RhoA, Rock1, Limk1, and Cofilin) and appropriate secondary antibody and
imaged using a Pierce ECL Substrate on ChemiDoc XRS+ System (Bio-Rad).
Population studies: Candidate Gene Association Resource (CARe) Consortium
The Candidate Gene Association Resource (CARe) population was used to evaluate 22
SNPs in the homologous region to the kidney injury locus identified in the present study.
The CARe consortium evaluated the association of renal function measures in
approximately 23,000 individuals of European descent18 using the IBC SNP array, a 50K
SNP genotyping array of candidate genes and pathways related to cardiovascular,
inflammatory and metabolic phenotypes19.
Statistical Analysis
Statistical analysis was performed using SPSS (Chicago, IL) for described animal studies.
RPT data was evaluated using an independent t-test using SPSS (Chicago, IL). Congenic
strain phenotype data (e.g., proteinuria, blood pressure, etc.) were evaluated by t-test and/or
by one-analysis of variance followed by Bonforni correction for multiple comparisons. A
p<0.05 was considered to be statistically significant. All data are presented as mean ±
standard error (SE). Survival was evaluated by the Kaplan-Meier method (Graphpad Prism
5, La Jolla, CA). A detailed description of the statistical approach for the CARe study is
provided in expanded material and methods section.
RESULTS
Fine-Mapping and Renal Hemodynamics
An overview of the approach used to fine-map and identify the genetic variants linked to the
proteinuria locus (kidney injury) on chromosome 2 is shown in Figure S1. Recombinant
progeny testing (RPT) was previously utilized to localize the chromosome 2 genetic locus to
a ~6Mb genomic interval (D2Arb11-D2Rat230). In the present study, RPT using additional
recombinant families further refined the genetic locus (in the S rat) to ~2.5 Mb (Fig. S2;
Table S1). Important recombinant animals were used to generate two small congenic strains
[S.SHR(2)X39 and X47] to characterize the influence of blood pressure, proteinuria, and
renal hemodynamic parameters associated with the kidney injury locus (Fig. 1). At 12 weeks
of age on low-salt diet (0.3% NaCl) blood pressure was similar between strains. However,
the S.SHR(2)X39 congenic demonstrated a ~2-fold reduction in proteinuria and significantly
Williams et al. Page 4










higher GFR compared to S rat (Fig. 2A). The S.SHR(2)X47 strain exhibited significantly
reduced proteinuria from week 8-20 and less kidney hypertrophy (Fig. S3). At week 20,
proteinuria was 109±12.2 mg/24hr compared to the 161±11.8 in the S. Similar to
SHR(2)X39, no significant difference in BP was detected in the S.SHR(2)X47 compared to
control S over the same period.
Proteinuria, renal hemodynamics, and survival was evaluated between the S and
S.SHR(2)X39 on a normal rodent diet (0.7% NaCl) (Fig. 2B, Fig. S4). The diet exacerbated
hypertension and accelerated the severity of proteinuria in both strains compared to a low-
salt-diet. However, the S.SHR(2)X39 congenic still exhibited a significant reduction in
proteinuria and improved kidney function (creatinine clearance) compared to S (Fig. 2B).
Renal blood flow (RBF) remained relatively constant when renal perfusion pressure (RPP)
varied from 100 to 140 mmHg (Fig. S4). Basal RBF was significantly higher in the congenic
(4.4±0.33 ml/min/g kidney weight; p<0.05) compared to S (3.0±0.27); however,
autoregulation of RBF was similar in the S and S.SHR(2)X39 strain (Fig. S4). Renal
vascular resistance was significantly decreased in the congenic (37±3.4 mm Hg/mL/min;
p<0.05) compared to S (53±4.2). The median survival for S.SHR(2)X39 rats was 345 days
compared with median survival of S rats (176 days, p<0.001), whereas no SHR died during
the course of the experiment (Fig. 2C).
Glomerular Morphology and Renal Pathology
Representative histology is shown for S and S.SHR(2)X39 congenic in Figure 3. Glomerular
injury (mesangial expansion, glomerulosclerosis, etc) was significantly attenuated in the
S.SHR(2)X39 strain compared to S as was glomerular area, whereas increased glomerular
hypertrophy was observed in S rats (Fig. 3B). Increased glomerular area was significantly
correlated with increased proteinuria (r=0.72, p<0.001). Nephron number was observed to
be significantly increased in the congenic strain. Despite a significant difference in
proteinuria between strains, glomerular permeability to FITC-albumin was similar (Fig. S4).
The extent of tubular injury and degree of interstitial fibrosis (tubule atrophy, immune cell
infiltration, and/or fibrosis) was significantly reduced in the S.SHR(2)X39 (Fig. 3) and
S.SHR(2)X47 (Fig. S3) compared to the S. No difference in medial thickness of the renal
arterioles between strains (Fig. 3C-D) was observed. The degree of interstitial injury was
confirmed by decreased α-SMA expression and macrophage infiltration observed in the
S.SHR(2)X39 (Fig. 3E-F) and S.SHR(2)X47 (Fig. S3) compared to the S.
Haplotype Analysis and Overlap with Human Kidney Disease
Haplotype analysis was performed using a panel of inbred strains known to exhibit high or
low proteinuria (Table S3). There was a strong concordance between the groups (high or
low) and the allelic variant (C or T) at ENSRNOSNP2786652. The S, MWF, BUF, and
MNS (susceptible to proteinuria) all possess the C allele, whereas the SHR, WHY, ACI,
F344, LOU, and MHS (resistant to proteinuria) possess the T allele. The location of SNP is
consistent with the region identified using substitution analysis (Fig. 4). However, the SNPs
above and below ENSRNOSNP2786652 did not exhibit this pattern (Table S3).
The region in humans that is homologous to the rat QTL lies on both human chromosome 1
and 4 (Fig. 4). The break point occurs around the middle of the rat QTL and provides
additional confirmation and refinement of the genomic interval by comparative mapping as
only the homologous region on 1q21 is linked to several forms of kidney disease (Fig. 4).
Sequencing, Expression, and Prioritization of Candidate Genes
The coding regions of genes that map into the congenic interval were sequenced from S and
SHR. A complete list of genes is shown in Table S4. Only genes that exhibited sequence
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differences are shown in Table 1. A total of 13 nonsynonymous (amino acid change) and 23
synonymous variants were identified in 16 genes. However, only 9 genes exhibited sequence
differences in the refined genomic interval considering substitution analysis, haplotype, and
comparative mapping data (summarized in Fig. 4). More than half of the sequence variants
(15/26) were found within three genes, Arhgef11, Pear1, and Iqgap3. Arhgef11 contained
the most nonsynonymous variants (n=3), followed by Iqgap3 (n=2) and Pear1 (n=1).
The expression of genes in the kidney was evaluated using a multiplex approach (Fig. S5).
Five genes (Arhgef11, Pear1, Sh2d2, Gpatch4, and Lrcc) were found to be differentially
expressed (Table S5). A subset of genes located in the refined interval were confirmed using
real-time PCR at an early (week 4) and late (week12) time point under low-salt diet (0.3%
NaCl) (Fig. 5A). Arhgef11, Pear1, Sh2d2, and Nes were confirmed to be differentially
expressed between strains, similar to the multiplex approach. Gene expression was also
evaluated on isolated kidney cortex and medulla from animals exposed to a moderate
increase in salt (0.7% NaCl). Arhgef11, Pear1, Sh2d2a, Nes, and Gpatch4 were again found
to be differentially expressed, but predominantly in kidney cortex (Fig. 5B). The S transcript
for each gene was expressed at a higher level as compared to the congenic irrespective of
diet, except for Nes or Gpatch4.
To establish gene(s) that may have the greatest likelihood for involvement in influencing
kidney injury, genes were evaluated based on three criteria, including nature and type of
sequence variation, differential expression, and/or possible biological role (Fig. S6). In
short, genes designated as high priority are those that exhibited coding sequence variants
that alter amino acids, differential expression, and evidence that the gene could have
biological role in the kidney. Arhgef11, Pear1, and Sh2d2 were identified as important
candidate genes linked to kidney injury using this methodology (Fig. 4).
Western Blot Analysis of ARHGEF11, Rho-ROCK Pathway, and Inhibition by Fasudil
The potential role of Arhgef11 in the Rho-ROCK pathway was evaluated by western blot
analysis as this pathway is known to influence cardiovascular disease (Fig. 6A-B). Protein
levels of ARHGEF11 were 1.6 fold higher in the S compared to the S.SHR(2)X39 congenic,
consistent with detected gene expression differences (Fig. 5). RhoA, which is activated
through exchange of GDP for GTP by ARHGEF11, was also increased in the S (1.5 fold) as
were other downstream proteins (ROCK1, LIMK1, p-Cofilin). Protein levels of ROCK1
demonstrated the greatest change (4.7 higher in the S).
The influence of the Rho-ROCK pathway on proteinuria was examined in the S,
S.SHR(2)X39, and SHR using the ROCK inhibitor fasudil (Fig. 6C). S rats treated with
fasudil demonstrated a significant reduction in proteinuria compared to untreated S rats at
week 10 and 12 (2 or 4 weeks treatment). Proteinuria at week 12 for S treated was similar to
S.SHR(2)X39. No difference in proteinuria was detected between treated and untreated
groups for either the S.SHR(2)X39 congenic or SHR.
Correlation of the Region with Human GWAS
eGFR (estimated glomerular filtration rate) data was available for 23,247 individuals of
European descent from the Candidate Gene Association Resource (CARe) Consortium.
Among the 22 SNP examined in the region homologous to the rat locus, a significant
association with eGFR was observed for rs7534418 (p= 0.001315, MAF= 0.3269, beta=
0.0069 for each copy of the T allele) after Bonferroni correction (Fig. 7). Additional nominal
associations (P<0.05) for several other SNPs (rs4661229, p=0.004; rs2768744, p=0.004)
were also observed. For UACR (urine albumin:creatinine ratio), (N=19,214), no associations
in the region were observed (Fig. S7).
Williams et al. Page 6











We previously reported that a region on rat chromosome 2 was associated with proteinuria,
histological renal injury, but not blood pressure9. A congenic strain was developed
[S.SHR(2)] to confirm the linkage analysis that demonstrated attenuated renal injury
independent of changes in blood pressure compared to control S12. Subsequently,
recombinant progeny testing (RPT) narrowed the genomic interval based on overlapping
recombinant intervals12. In the present study, we utilized additional RPT to better define the
genomic interval, developed two small congenic strains to characterize the cardiovascular
and renal parameters associated with the genomic locus, as well as performed detailed
genetic analysis (haplotype analysis, sequencing, and gene expression) to identify genetic
variants that may be causative to the observed renal injury.
Both congenic strains demonstrated reduced kidney injury and improved kidney function
compared to the control S. The decreased proteinuria and improved GFR was associated
with reduced renal inflammation and interstitial fibrosis in the absence of measurable
differences in BP between strains. Increased nephron number, along with elevated GFR in
the S.SHR(2)X39 congenic, suggests that kidney development may play a role in the
improved kidney function compared to the S, which exhibited significantly less nephrons.
The connection between low nephron number and the risk of hypertension and kidney
disease has been shown in humans and experimental animal models20. Glomerular
permeability was similar between strains, despite the S.SHR(2)X39 congenic strain
exhibiting a ~40% reduction in proteinuria compared to the S rat. This suggests that the
detected difference in proteinuria is not likely due to the degree of filtered protein, but may
likely reflect an increase in the reuptake of filtered protein in the proximal tubules. This
finding is consistent with other genetic models of renal disease in which a large fraction of
proteinuria is attributed to an impairment of protein reuptake via the proximal tubule without
changes in glomerular permeability21.
Classification of the nature and type of sequence variation, differential expression, and
potential biological role identified three genes (Arhgef11, Pear1, Sh2d2a) as important
candidates for involvement in kidney injury. In general, allelic variants (promoter, coding,
or intronic) in any of these genes could play important roles in influencing the onset or
progression of kidney injury, either by altering gene expression, protein function, and/or
alternative splicing. For example, Pear1 is a novel membrane protein involved in platelet
contact -induced activation22. Platelet activation and endothelial dysfunction have been
mostly linked to atherosclerotic disease23 and results in the secretion of several types of
chemokines (MCP1, CCL5, CXCL4, etc.)24. The release of these chemokines triggers
monocyte recruitment, differentiation into macrophages24, and perhaps immune-mediated
renal injury. Sh2d2a is a T-cell specific adapter protein (or TSAd). Recent studies have
indicated that it may function predominately in the nucleus where it acts to regulate the
transcription of different T-cell target genes, including IL-225. TSAd-/- deficient mice are
susceptible to lupus-like autoimmune disease (when challenged with pristine) and
demonstrate glomerulonephritis and proteinuria at an advanced age26. This type of renal
injury is likely secondary to autoimmune disease by immune complexes becoming deposited
in kidney glomeruli.
The most convincing evidence exists for Arhgef11 being involved in kidney injury in the
Dahl S. ARHGEF11 is Rho guanine nucleotide exchange factor that participates in the Rho-
ROCK pathway. The Rho-ROCK pathway has been implicated in a variety of pathological
conditions including cardiovascular disease and neurological disorders27, 28. The Rho family
of small GTPases regulate a number of cell functions, including actin cytoskeletal
organization, cell adhesion, cell motility, vascular smooth muscle contraction, and gene
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expression29. ARHGEF11 (PDZ-RhoGEF) binds activated α12/13 (G-protein) and
demonstrates specificity for activating RhoA, but not other Rho family members, Rac1 and
Cdc4230. ARHGEF11 catalyzes the exchange of GDP for GTP thereby activating RhoA31.
The Rho effector protein, ROCK, is a serine-threonine kinase involved in both
phosphorylation of myosin light chain (MLC) which can contribute to stress fiber formation
and smooth muscle contraction. Arhgef11-deficient zebrafish embryos exhibit kidney cysts
(along with other phenotypes) and the distribution of F-actin in the pronephric ducts is
altered32. This work provides some evidence that Arhgef11 can affect kidney development
and play a role in stress fiber formation.
The Rho-ROCK pathway is modestly up-regulated in the S [compared to S.SHR(2)X39],
suggesting that chronic stimulation of the pathway may account for progressive kidney
injury in the S. At this point, it is not clear if the pathway is up-regulated due to differential
expression or protein function differences based on amino acid changes between the S and
SHR. However, our data is consistent with other studies that support a role for Rho-ROCK
with various aspects of renal disease, including alterations in afferent arteriolar tone (via
VSMC)33, podocyte dysfunction34, and tubular EMT leading to fibrosis (TGF-β
mediated)35, 36.
There are two ROCK inhibitors available, Y-27632 and fasudil, both of which have been
extensively used to investigate the role of Rho kinase in cardiovascular disease37. Both
compounds attenuate tubulointerstitial fibrosis in a mouse model of unilateral ureteral
obstruction (UUO)38. Inhibition of ROCK (fasudil) has also been shown to attenuate the
development of glomerulosclerosis in the Dahl salt-sensitive rat39. Improvement in
glomerulosclerosis was not accompanied by changes in BP 39. Inhibition of the Rho-ROCK
pathway using fasudil significantly lowered proteinuria in S treated vs. non-treated and no
difference was observed between treated and non-treated congenic or SHR. This suggests
that low-dose treatment with fasudil does not significantly affect the Rho-ROCK pathway in
the congenic or SHR because these strains are able to correctly regulate the pathway. These
findings demonstrate that allelic variants in Arhgef11, acting through the Rho-ROCK
pathway, could modulate renal protection independent of changes in blood pressure (but
function on a hypertensive susceptible genetic background).
The evaluation of the rat genomic locus using the human CKD CARe population supports
our view that genetic variants/genes identified using rat models of renal disease may lead to
a better understanding of genetic factors that contribute to kidney disease in humans. None
of the candidate genes identified in the present study (Arhgef11, Pear1, Sh2d2a) have been
associated with proteinuria or GFR in humans until now. Several human studies have found
an association with genetic variants in these genes with other types of cardiovascular,
metabolic, or inflammatory diseases. In this regard, SNPs in ARHGEF11 have been linked
to diabetes40 and susceptibility to cerebrovascular disease (intracranial aneurysm)41.
ROCK2 (a downstream target of ARHGEF11-RHOA) is associated with lower risk of
hypertension in HYPGENE study42. Genetic variants in PEAR1 are associated with
increased platelet response43 and genetic variants in the promoter region of SH2D2A (short
allele in promoter region) are linked with susceptibility to multiple sclerosis44 and juvenile
rheumatoid arthritis45, both chronic immune mediated diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Linkage analysis usually only identifies a broad genomic region linked to a particular
trait and subsequent fine-mapping is required to identify the causal genetic elements.
Ultimately, it is necessary to conducted detailed physiological studies using a small
congenic strain to explore the mechanism linked to the causative gene or genetic variants.
Here, we provided detailed information on cardiovascular and renal hemodynamic
parameters associated with genetic variants on rat chromosome 2 that strongly influences
the development of kidney injury in the S rat. It is clear that functional significance of the
identified candidate genes and sequence variants will require more detailed analysis, but
convincing evidence exists that Arhgef11 may be linked to kidney injury in the Dahl S
via the Rho-ROCK signaling pathway. In summary, this work provides an advance in
identifying genetic variants/ genes that modulate the onset and progression of kidney
disease in the setting of hypertension using the Dahl S rat and establishes relevance to
human CKD using the CARe population.
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1. What is New?
• First report on the high-resolution localization of a genomic locus linked to
hypertensive related kidney disease using the Dahl salt-sensitive (S) rat, a model
of human CKD.
• Few studies have performed, as we have, detailed physiological studies,
histological analysis, comprehensive sequence and gene expression analysis to
investigate mechanism linked to a fine-mapped genetic locus for kidney injury.
• Identified a strong candidate gene (Arhgef11), not previously linked to the
development of kidney injury in the rat and showed the locus around this gene
was associated with eGFR in humans.
2. What is Relevant?
• Our genetic studies utilize two models of hypertension (S and SHR) that differ
with respect to kidney injury. The advantage of this comparison is the ability to
identify loci that influence kidney injury on genetic backgrounds (either S or
SHR) permissive for hypertension.
• Hypertension is the second leading cause of renal failure in humans. Thus,
identification of gene/genetic variants related to kidney injury in the context of
hypertension could have a significant impact on human health by serving as
novel therapeutic targets.
3. Summary
Our previous studies utilized the Dahl salt-sensitive (S) rat to identify broad genomic
intervals linked with cardiovascular and kidney disease. We now have successfully
narrowed the genomic segment and identified specific genetic variants and genes on
chromosome 2 linked with injury and reduced renal function. Thus, this work provides a
significant advance in identifying genetic variants that contribute to the development of
kidney disease in the setting of hypertension and establishes relevance to human CKD
using the CARe population.
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High-resolution localization of genomic region linked to kidney injury on rat chromosome 2.
(A) Ideogram showing the 95% confidence interval (CI) for the quantitative trait loci (QTL)
from original linkage analysis (solid black bar)9, 95% CI from second larger population,
n=993 (open bar)12 and current refinement of kidney injury locus to a <2 Mb based on
substitution analysis (red box). (B) Enlargement of the genomic region and two small
congenic strains important in delimiting the genomic region. The grey box denotes the
location of QTL based on RPT (Fig. S2) and X47 strain. The red solid bars to the right of the
physical map with relevant microsatellite markers indicate the extent of the SHR-donor
regions on the S background.
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Blood pressure, proteinuria, and renal hemodynamic parameters between S, S.SHR(2)X39,
and SHR. (A) Mean arterial pressure (MAP), proteinuria and glomerular filtration rate
(GFR) at week 12 for animals (n=6-8 per group) raised on low-salt. (B) Proteinuria and
creatinine clearance (CrCl) for animals raised on Purina 5010 (0.7% NaCl) diet (n=9 per
group). (C) Kaplan-Meier survival curve. For panels B and C, animals were raised on low-
salt (0.3% NaCl) until 6 weeks of age and then placed on Purina 5010 (0.7% NaCl) diet for
duration of experiment to accelerate injury. *, p<0.05 vs. S and/or SHR. #, p<0.05 vs. S or
S.SHR(2)X39.
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Assessment of renal injury between S and S.SHR(2)X39 at week 12 raised on Purina 5010
(0.7% NaCl). (A) Representative light microscopy image from each strain, including whole
kidney section, glomerulus, tubulointerstitial region, and renal vessel. (B) Semi-quantitative
and morphometric analysis of individual glomeruli assessed for degree of
glomerulosclerosis and mesangial expansion [scale from 0 (normal) to 4 (global sclerosis])
and glomerular area was determined. (C) Morphometric analysis of tubular injury and
interstitial fibrosis. (D) Measurement of vessel wall thickening. Vessel wall thinking (vessel
media, um2) was calculated by measuring the outer circumference of the vessel minus the
inner circumference of the lumen (20 random images per animal, n=9 animals per group).
(E-F) Representative immunohistochemical images of α-smooth muscle actin (SMA) and
CD-68 (ED-1; macrophage). n=8 per group. *, p<0.05
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Summary of refinement of genomic locus using substitution analysis, comparative mapping,
haplotype analysis, and identification of key genes. The gray box (left panel) denotes the
location of the QTL based on RPT (Fig. S2) and smallest congenic strain, S.SHR(2)X47
(Fig. 1). The region in humans that is homologous to the rat QTL lies on both human
chromosome 1 and 4 (middle panel). The break point (between 178.523 and 179.114 Mb)
occurs around the middle of the rat QTL and provides a means to further refine the genomic
interval. Human chromosome 1 has been linked to kidney disease, (1) Adult onset
nephropathy and hypertension 10; (2) MCDK1, medullary cystic kidney disease 46-48; and
(3) creatinine clearance (HyperGen study) 11, whereas no human linkage or GWAS studies
have been associated with kidney disease on chromosome 4. The panel on the right shows
important SNP used for haplotype analysis (Table S3). The SNP shown in red demonstrated
an association between high or low proteinuria strains, whereas those SNP in blue did not.
The underlined genes (Arhgef11, Pear1, and Sh2d2) were identified as high priority using
gene priority decision-tree (Fig. S6) and exhibit sequence variants that altered amino acid(s),
exhibited differential expression, and linked to a possible biological role in the kidney. The
remaining genes on the left of the physical map either exhibit sequence variants, or
differential expression. The genes on the right of the physical map exhibited no coding
sequence variants or differential expression. The star denotes the SNP (rs7534418)
associated with eGFR in the CARe study described in this study (Fig. 7).
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Quantitative real-time PCR of candidate genes. (A) Gene expression at week 4 and week12
under low-salt (0.3% NaCl). (B) Gene expression evaluated on isolated kidney cortex and
medulla from animals exposed to a moderate increase in salt (0.7% NaCl). *, p<0.01. Ratio
>1, S transcript expressed at higher level than congenic; Ratio <1, congenic expressed at
higher level than S transcript. ND=not detected, n=6 per group.
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Western blot of Rho-ROCK pathway and pharmacological inhibition of the using fasudil.
(A) Western blot analysis of the Rho-ROCK pathway between the S and S.SHR(2)X39 on
Purina (0.7% NaCl) at week 12 (same samples as Fig. 3). Protein levels of ARHGEF11 and
key proteins in the Rho-ROCK signaling pathway (n=6 per group). A representative image
of GAPDH is shown to demonstrate similar protein loading. (B) Densitometry measurement
of each protein normalized to GAPDH. GAPDH was probed along with each protein (i.e.
each protein was normalized to GAPDH probed on same blot as protein). (C) Treatment of
S, S.SHR(2)X39, and SHR with Rock inhibitor fasudil. At week 8, animals for each strain
were randomly assigned to either control (n=5 per strain) or fasudil treatment (n=6 per
strain). Fasudil was provided in drinking water to achieve a low dose of ~20 mg/kg/day. *
p<0.05 S verse other groups; #, p<0.05 S versus S treated with fasudil.
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Regional plot for the homologous candidate region associated with eGFR in humans (23,247
individuals). X-axis shows the genomic region and genes, and the y-axis shows the -log10 p
values for associations. The panel also shows the recombination rate in the region estimated
from HapMap CEU data and pairwise linkage disequilibrium (r2) between SNPs in the
region and the lowest p-value SNP (labeled in purple) estimated from the meta-analyses.
The r2 values are color coded according to the scale on each panel.
Williams et al. Page 20



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hypertension. Author manuscript; available in PMC 2013 November 01.
